The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.
Open accessAbstract
A second isoform of the human vesicular monoamine transporter (hVMAT) has been cloned from a pheochromocytoma cDNA library. The contribution of the two transporter isoforms to monoamine storage in human neuroendocrine tissues was examined with isoform-specific polyclonal antibodies against hVMAT1 and hVMAT2. Central, peripheral, and enteric neurons express only VMAT2. VMAT1 is expressed exclusively in neuroendocrine, including chromaffin and enterochromaffin, cells. VMAT1 and VMAT2 are coexpressed in all chromaffin cells of the adrenal medulla. VMAT2 alone is expressed in histamine-storing enterochromaffin-like cells of the oxyntic mucosa of the stomach. The transport characteristics and pharmacology of each VMAT isoform have been directly compared after expression in digitonin-permeabilized fibroblastic (CV-1) cells, providing information about substrate feature recognition by each transporter and the role of vesicular monoamine storage in the mechanism of action of psychopharmacologic and neurotoxic agents in human. Serotonin has a similar affinity for both transporters. Catecholamines exhibit a 3-fold higher affinity, and histamine exhibits a 30-fold higher affinity, for VMAT2. Reserpine and ketanserin are slightly more potent inhibitors of VMAT2-mediated transport than of VMAT1-mediated transport, whereas tetrabenazine binds to and inhibits only VMAT2. N-methyl-4-phenylpyridinium, phenylethylamine, amphetamine, and methylenedioxymethamphetamine are all more potent inhibitors of VMAT2 than of VMAT1, whereas fenfluramine is a more potent inhibitor of VMAT1-mediated monamine transport than of VMAT2-mediated monoamine transport. The unique distributions of hVMAT1 and hVMAT2 provide new markers for multiple neuroendocrine lineages, and examination of their transport properties provides mechanistic insights into the pharmacology and physiology of amine storage in cardiovascular, endocrine, and central nervous system function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Fuerst, T. R., Niles, E. G., Studier, F. W., & Moss, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.21.8122 · Cited by 2,089
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263
An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2
Seed, B. (1987) · Nature · doi:10.1038/329840a0 · Cited by 681
Rindi, G., Luinetti, O., Cornaggia, M., Capella, C., & Solcia, E. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90266-f · Cited by 644
A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter
Liu, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90425-c · Cited by 594
Rudnick, G., & Wall, S. C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1817 · Cited by 535
Expression cloning of a reserpine-sensitive vesicular monoamine transporter.
Erickson, J. D., Eiden, L. E., & Hoffman, B. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10993 · Cited by 487
Self-citationDopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain
Ricaurte, G. A., Guillery, R. W., Seiden, L. S., Schuster, C. R., & Moore, R. Y. (1982) · Brain Research · doi:10.1016/0006-8993(82)90198-6 · Cited by 479
Cited by
Histamine in the Nervous System
Haas, H. L., Sergeeva, O. A., & Selbach, O. (2008) · Physiological Reviews · doi:10.1152/physrev.00043.2007 · Cited by 1,228
Mechanisms of neurotransmitter release by amphetamines: A review
Sulzer, D., Sonders, M. S., Poulsen, N. W., & Galli, A. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.003 · Cited by 1,209
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Mechanisms of Amphetamine Action Revealed in Mice Lacking the Dopamine Transporter
Jones, S. R., Gainetdinov, R. R., Wightman, R. M., & Caron, M. G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-06-01979.1998 · Cited by 631
How Addictive Drugs Disrupt Presynaptic Dopamine Neurotransmission
Sulzer, D. (2011) · Neuron · doi:10.1016/j.neuron.2011.02.010 · Cited by 581
Catecholaminergic systems in stress: structural and molecular genetic approaches
Kvetnansky, R., Sabban, E. L., & Palkovits, M. (2009) · Physiological Reviews · doi:10.1152/physrev.00042.2006 · Cited by 548
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Neurotransmitter Transporters in the Central Nervous System
Masson, J., Sagné, C., Hamon, M., & El Mestikawy, S. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01414-5 · Cited by 416
Schäfer, M. K.-H., Varoqui, H., Defamie, N., Weihe, E., & Erickson, J. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206738200 · Cited by 409
Self-citationKaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
Wang, Y.-M., Gainetdinov, R. R., Fumagalli, F., Xu, F., Jones, S. R., Bock, C. B., Miller, G. W., Wightman, R. M., & Caron, M. G. (1997) · Neuron · doi:10.1016/s0896-6273(00)80419-5 · Cited by 376
Dopamine transporters and neuronal injury
Miller, G. W., Gainetdinov, R. R., Levey, A. I., & Caron, M. G. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01379-6 · Cited by 371
The Neurotransmitter Cycle and Quantal Size
Edwards, R. H. (2007) · Neuron · doi:10.1016/j.neuron.2007.09.001 · Cited by 365
Anderson, K. E., Stamler, D., Davis, M. D., Factor, S. A., Hauser, R. A., Isojärvi, J., Jarskog, L. F., Jimenez-Shahed, J., Kumar, R., McEvoy, J. P., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30236-5 · Cited by 337
Embracing diversity in the 5-HT neuronal system
Okaty, B. W., Commons, K. G., & Dymecki, S. M. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0151-3 · Cited by 319
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Savani, A. A., & Login, I. S. (2007) · Neurology · doi:10.1212/01.wnl.0000259143.52138.5c · Cited by 299
The “Normal” Endocrine Cell of the Gut: Changing Concepts and New Evidences
RINDI, G., LEITER, A. B., KOPIN, A. S., BORDI, C., & SOLCIA, E. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.001 · Cited by 297
Duerr, J. S., Frisby, D. L., Gaskin, J., Duke, A., Asermely, K., Huddleston, D., Eiden, L. E., & Rand, J. B. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-01-00072.1999 · Cited by 282
Self-citationHoffman, B. J., Hansson, S. R., Mezey, É., & Palkovits, M. (1998) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1998.0168 · Cited by 279
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Monoamine transporters and psychostimulant addiction
Howell, L. L., & Kimmel, H. L. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.003 · Cited by 255
The gut as the largest endocrine organ in the body
Ahlman, H., & Nilsson, O. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s63 · Cited by 254
Vesicular and Plasma Membrane Transporters for Neurotransmitters
Blakely, R. D., & Edwards, R. H. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005595 · Cited by 169
“both isoforms recognize multiple monoamines as substrates, with a slightly higher apparent affinity for VMAT2 (Peter et al. 1994; Erickson et al. 1996).”
BackgroundVesicular monoamine transporter 2: Role as a novel target for drug development
Zheng, G., Dwoskin, L. P., & Crooks, P. A. (2006) · The AAPS Journal · doi:10.1208/aapsj080478 · Cited by 125
Hutson, P. H., Pennick, M., & Secker, R. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.014 · Cited by 72
Costorage of enteroendocrine hormones evaluated at the cell and subcellular levels in male mice
Fothergill, L. J., Callaghan, B., Hunne, B., Bravo, D. M., & Furness, J. B. (2017) · Endocrinology · doi:10.1210/en.2017-00243 · Cited by 63
Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test
Crowley, J. J., Brodkin, E. S., Blendy, J. A., Berrettini, W. H., & Lucki, I. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301065 · Cited by 61
“VMAT2 is a neuronally expressed subtype of the vesicular monoamine transporter responsible for loading synaptic vesicles with the monoamine neurotransmitters serotonin, norepinephrine, dopamine, and histamine (Liu et al, 1992; Peter et al, 1994; Erickson et al, 1992, 1996).”
BackgroundRecurrent Postural Vasovagal Syncope: Sympathetic Nervous System Phenotypes
Vaddadi, G., Guo, L., Esler, M., Socratous, F., Schlaich, M., Chopra, R., Eikelis, N., Lambert, G., Trauer, T., & Lambert, E. (2011) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.111.962332 · Cited by 54
Amphetamine releases dopamine from synaptic vesicles by dual mechanisms
Floor, E., & Meng, L. (1996) · Neuroscience Letters · doi:10.1016/s0304-3940(96)12963-3 · Cited by 54
Fasano, A., & Bentivoglio, A. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903386292 · Cited by 51
Divergent properties and independent regulation of striatal dopamine and GABA co-transmission
Zych, S. M., & Ford, C. P. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110823 · Cited by 46
“Studies on VMAT2 substrate affinity and inhibitor specificity have found different apparent affinities for various substrates and psychostimulants, including DA, 5-HT, histamine, MDMA, and MPP+ (Erickson et al., 1996; Gasnier et al., 1994; Peter et al., 1994); however, no studies have yet examined the affinity of VMAT…”
BackgroundStructural mechanisms for VMAT2 inhibition by tetrabenazine
Dalton, M. P., Cheng, M. H., Bahar, I., & Coleman, J. A. (2024) · eLife · doi:10.7554/elife.91973.4 · Cited by 14
Structural mechanisms for VMAT2 inhibition by tetrabenazine
Dalton, M. P., Cheng, M. H., Bahar, I., & Coleman, J. A. (2023) · doi:10.1101/2023.09.05.556211 · Cited by 6
Structural mechanisms for VMAT2 inhibition by tetrabenazine
Dalton, M. P., Cheng, M. H., Bahar, I., & Coleman, J. A. (2024) · doi:10.7554/elife.91973.3
Metadata
- Authors
- Erickson, J. D., Schafer, M. K., Bonner, T. I., Eiden, L. E., & Weihe, E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1996-05-14
- Volume
- 93
- Issue
- 10
- Pages
- 5166-5171
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2028372004
- Cited by
- 479
- References
- 36
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.